-

Toku Appoints Former Google Head of Cardiovascular Health as Chief Health Officer

SAN DIEGO--(BUSINESS WIRE)--Toku is delighted to announce the appointment of Professor Michael V. McConnell, MD, MSEE to the role of Chief Health Officer. Professor McConnell’s former roles include Director of Advanced Cardiovascular Imaging and Preventive Cardiology at Stanford University and Head of Cardiovascular Health Innovations at Google. He is also a founding member of the American Heart Association’s Health Tech Advisory Group and author of Fight Heart Disease Like Cancer.

Professor McConnell stated, “I am excited to join the Toku leadership team and to help advance early detection and prevention of major health conditions for people around the world. Toku brings together AI, noninvasive imaging, and preventative health making every eye exam an opportunity for a person to learn if they have a serious health risk which could be mitigated with further guideline-based evaluation and care.”

Toku’s CEO, Associate Professor Ehsan Vaghefi, noted “I have long been impressed by Mike’s work at Stanford on imaging and prevention and his contribution to Google’s highly cited paper on AI in cardiovascular risk assessment through imaging of the eye. Mike combines clinical and research expertise, successful business experience, and a passion to have a global impact. We are extremely lucky to have him on the Toku team.”

About Toku, Inc.

Toku, Inc. based in San Diego CA, is a cutting-edge technology company that specializes in converting routine eye exams to comprehensive health screening by developing AI-powered tools. The company’s first commercialized product, BioAge, uses AI to analyze biometric markers in the retina to accurately identify an individual’s biological age. Toku’s second product, CLAiR has received Breakthrough Device designation from the United States FDA. Toku is committed to making its technology widely accessible through major partnerships across the world. Toku’s Series A financing was co-led by National Vision, Inc., one of the largest optical retailers in the United States, and Topcon Healthcare, a leading provider of medical devices and intelligent software solutions for the global eye care community.

Toku will be attending the American College of Cardiology (ACC) 2024 meeting, taking place April 6-8 in Atlanta, GA. During the conference, Toku will showcase its BioAge technology as part of the Future Hub, present a scientific poster and participate in the ACC24 Pitch Competition on Sunday 7 April at 3.30pm.

Contacts

Toku, Inc.


Release Versions

Contacts

More News From Toku, Inc.

Toku welcomes Dr Robert Weinreb to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Toku is pleased to announce the appointment of Robert N. Weinreb MD to its Board of Directors. Renowned globally for his contributions to ophthalmology, Dr. Weinreb's appointment underscores Toku's commitment to excellence and innovation in eye care. “We are thrilled to welcome Dr. Weinreb to our Board! Working with him, we will accelerate our leadership in healthcare through the eye,” according to Ehsan Vaghefi, President and CEO. Dr. Weinreb's distinguished career...

Toku Inc. Secures FDA Breakthrough Designation for Technology that Identifies Chronic Kidney Disease Risk Through the Eye

SAN DIEGO--(BUSINESS WIRE)--Toku, Inc., a commercial medical device company specializing in imaging technology and AI, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its MyKidneyAI technology. MyKidneyAI uses AI to analyze retinal images collected at routine eye exams to detect elevated chronic kidney disease (CKD) risk in people with diabetes. Most people with diabetes are not routinely screened for CKD today, resulting in the di...

Toku Obtains CE and UKCA Marks for AI Cardiovascular Risk Assessments Through the Eye

SAN DIEGO--(BUSINESS WIRE)--Toku, Inc., a commercial medical device company specializing in AI assessment of retinal images, announced today that it has obtained CE and UKCA Marks for its patented CLAiR technology. This significant milestone underscores Toku’s commitment to maintaining the highest standards of quality and safety and allows access to the Europe and United Kingdom markets. CLAiR provides accurate, affordable, non-invasive evaluation for the risk of cardiovascular disease (CVD) at...
Back to Newsroom